Catherine Boutsikakis on The Complexities of Hemophilia
Catherine Boutsikakis, Managing Pharmacist – Patient Pharmacy at Cure 4 The Kids Foundation, shared on LinkedIn:
”Thank you Pharmacy Times for the opportunity to discuss the complexities of hemophilia, new treatments available, and the impact on patients and families.”
Watch the full discussion here.
Hemophilia is classified as mild, moderate, or severe based on clotting factor activity, which determines its clinical presentation.
Severe hemophilia is characterized by spontaneous bleeding, especially into joints and muscles, often resulting in chronic pain, limited mobility, and progressive joint damage.
Moderate hemophilia typically leads to bleeding after minor injuries, whereas mild cases usually bleed only with significant trauma or surgical procedures.
Recognizing this spectrum helps clinicians anticipate complications, individualize treatment strategies, and reduce long-term morbidity while preserving quality of life.”
Stay updated with Hemostasis Today.
-
Apr 13, 2026, 12:17Tareq Abadl: Irradiated Blood – Safer, Not More Dangerous
-
Apr 13, 2026, 12:11Chokri Ben Lamine: Thread Platelet Subpopulations Leads to Therapeutic Implications
-
Apr 13, 2026, 11:49Jecko Thachil: Why Splenectomy Increases Thrombosis Risk and How We Can Prevent It
-
Apr 13, 2026, 11:31Sumyea Kabir: The Hidden Risk of Bombay Blood Group
-
Apr 13, 2026, 10:57José Antonio García Erce: Situation of Immunoglobulins in Spain
-
Apr 13, 2026, 09:51Caitlin Raymond: Jehovah’s Witnesses Can Now Accept Their Own Blood But It Is Still Not That Simple
-
Apr 13, 2026, 09:12We Are Pleased to Welcome Rajneesh Jain as the New Chief Executive Officer – Hemophilia Federation (India)
-
Apr 13, 2026, 08:52Deborah Holzapfel: The Reality for Women with Hemophilia B
-
Apr 13, 2026, 08:35Sara Altayeb: ESC 2026 Clinical Pearls for Bleeding on Anticoagulation